Abstract
The series of polyurethaneurea (PUU) containing in its structure the fragments of the copolymer of N-vinylpyrrolidone, vinyl acetate and vinyl alcohol (VP-VA) with the 1.6-hexamethylenediamine (HMDA) macrochain extender and the series of PUU with the 4.4'-diaminodiphenylmethane (DADPh) macrochain extender having different ratio of HMDA and DADPh to VP-VA (30:70; 40:60; 50:50; 60:40; 70:30) were synthesized. It has been established that PUU containing in its structure the DADPh macrochain extender is characterized by higher values of the tensile strength and relative elongation at break, glass-transition temperature and the change of the specific heat capacity and hydrophilicity compared to PUU containing in its structure the HMDA macrochain extender. It was found that the increase in amount of VP-VA copolymers in PUU structure increases hydrophilicity by 19-41% for PUU with HMDA and by 16-62% for PUU with DADPh and will contribute to a prolonged release of biologically active substances from the polymer matrix. The results obtained allowed us to determine that the PUU with VP-VA copolymer fragments in the structure synthesized with the ratio of HMDA and DADPh to VP-VA 70:30 is characterized by sufficient physical-mechanical properties (σ = 3.1 MPa, e = 47% and σ = 5.2 MPa, e = 90%, accordingly), hydrophilicity (21.0% and 19.4%, accordingly) and can be used as a polymer matrix for medicine biologically active composite materials.
Highlights
For polymer materials synthesized with the HMDA macrochain extender, PUU not containing vinylpyrrolidone copolymer with vinyl alcohol (VP-VA) copolymer possessed the highest values of physical-mechanical properties (σ = 6.6 MPa, ε = 544%) (Table 1)
The data presented (Table 1, Table 2) allow suggesting that PUU with VP-VA copolymer fragments in the structure synthesized with the ratio of HMDA and DADPh to VP-VA 70:30 possesses sufficient physical-mechanical properties (σ = 3.1 MPa, ε = 47% and σ = 5.2 MPa, ε = 90%, ) and hydrophilicity (21.0% and 19.4%, ) to be used as polymer matrix for medicine biologically active composite materials with prolonged release of biologically active substances
The series of PUU containing in its structure the VP-VA copolymer fragments with either the HMDA or DADPh macrochain extender and a different ratio of components have been synthesized
Summary
The polyurethaneurea (PUU) are used in a variety of medical applications, such as the wound dressing [1], contact lenses [2], catheters, prostheses, blood vessels [3], antithrombogenous products [4], mechanically supporting constructions during the soft tissue reconstruction [5], metal stents coating of atherosclerotic blood vessels [6], surgical meshes [7, 8] and bone tissue engineered [9, 10], vascular tissue engineering [11].The presence in PUU macrochain of the urethane groupO ( NH C O ) similar in chemical structure to the peptide group of proteins (―CO―NH―) provides widespread use of PUU in medical practice due to their biocompatibility.Hydrophilicity is an important characteristic of medical polymer material matrix, because it generally ensures prolonged release of the therapeutic substance (TS) from the polymer matrix in vivo. O ( NH C O ) similar in chemical structure to the peptide group of proteins (―CO―NH―) provides widespread use of PUU in medical practice due to their biocompatibility. The film materials with Decamethoxine based on polyurethaneurea containing the fragments of the VP-VA copolymer have been already developed. Such material with antimicrobial effect is recommended for healing wounds and burns [13]. It is known [14], that diaminе-containing PUU with folic acid, which provides regenerative properties, allows the use it as burns coatings in medicine. Preparing film materials with improved properties based on hydrophilic PUU remains to be an important task
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
